Abstract 5056
Background
Cemiplimab-rwlc is the only US FDA-approved treatment for patients (pts) with advanced CSCC. The primary analysis of a weight-based regimen of cemiplimab 3 mg/kg IV dosed every 2 weeks (Q2W) in mCSCC has been published; follow-up data are reported here. The primary analysis for the approved fixed-dosing regimen of cemiplimab 350 mg IV dosed every 3 weeks (Q3W) in mCSCC, which displays comparable pharmacokinetics to weight-based dosing, is also reported.
Methods
In a phase II study (NCT02760498), pts with mCSCC received IV cemiplimab as a weight-based regimen for up to 96 weeks (Group [Gp] 1, n = 59) or a fixed regimen for up to 54 weeks (Gp 3, n = 56). The primary objective was objective response rate (ORR) per independent central review (ICR; RECIST 1.1 for scans, modified WHO criteria for photos).
Results
Baseline characteristics were similar in both gps (Table). Median (range) duration of follow-up was 16.5 (1.1–26.6) months (mos) for the Gp 1 update and 8.1 (0.6–14.1) mos for the Gp 3 primary analysis. ORR (95% confidence interval [CI]) by ICR was 49.2% (35.9–62.5%) in Gp 1, 39.3% (26.5–53.2%) in Gp 3, and 44.3% (35.1–53.9%) for both gps combined. ORR by investigator assessment was 49.2% (35.9–62.5%) in Gp 1, 51.8% (38.0–65.3%) in Gp 3, and 50.4% (41.0–59.9%) combined. Median duration of response (DOR) per ICR has not been reached (range: Gp 1, 2.8–21.6 mos; Gp 3, 2.1–11.1 mos). Estimated 12-month DOR (95% CI) per ICR was 88.9% (69.3–96.3%) in Gp 1 and not evaluable in Gp 3. Similar proportions of pts in both gps experienced an adverse event (AE), most commonly diarrhea, fatigue, and nausea (Table). Grade ≥3 AEs were reported in 45.2% (52/115) of pts in both gps combined, most commonly anemia (6.1%, 7/115).Table:
1318P
Group 1 (IV cemiplimab 3 mg/kg Q2W) n = 59 | Group 3 (IV cemiplimab 350 mg Q3W) n = 56 | Total n = 115 | |
---|---|---|---|
Demographics | |||
Median age, years (range) | 71 (38–93) | 71 (38–90) | 71.0 (38–93) |
Male, n (%) | 54 (91.5) | 48 (85.7) | 102 (88.7) |
Eastern Cooperative Oncology Group performance status score = 0, n (%) | 23 (39.0) | 25 (44.6) | 48 (41.7) |
Eastern Cooperative Oncology Group performance status score= 1, n (%) | 36 (61.0) | 31 (55.4) | 67 (58.3) |
Primary CSCC site: Head and neck | 38 (64.4) | 31 (55.4) | 69 (60.0) |
Prior cancer-related systemic therapy | 33 (55.9) | 20 (35.7) | 53 (46.1) |
Prior cancer-related radiotherapy | 50 (84.7) | 38 (67.9) | 88 (76.5) |
Median duration of exposure, weeks (range) | 65.0 (2.0–96.1) | 34.3 (2.6–60.4) | 40.1 (2–96) |
Median number of doses administered (range) | 31.0 (1–48) | 11.5 (1–20) | 14.0 (1–48) |
Efficacy | |||
Durable disease control rate (stable disease or response for ≥16 weeks) per ICR, % (95% CI) | 62.7 (49.1–75.0) | 55.4 (41.5–68.7) | 59.1 (49.6–68.2) |
Median time to response per ICR, months (range) | 1.9 (1.7–9.1) | 2.1 (2.0–8.3) | 2.1 (1.7–9.1) |
Safety | |||
Patients with an AE of any grade, n (%) | 59 (100.0) | 54 (96.4) | 113 (98.3) |
Diarrhea | 17 (28.8) | 10 (17.9) | 27 (23.5) |
Fatigue | 15 (25.4) | 16 (28.6) | 31 (27.0) |
Nausea | 14 (23.7) | 10 (17.9) | 24 (20.9) |
Patients with a grade ≥3 AE, n (%) | 30 (50.8) | 22 (39.3) | 52 (45.2) |
Patients who discontinued treatment due to an AE, n (%) | 6 (10.2) | 3 (5.4) | 9 (7.8) |
Conclusions
The primary analysis of Gp 3 confirms that the approved dose of cemiplimab 350 mg IV Q3W confers comparable efficacy and safety to the weight-based regimen (Gp 1) in mCSCC. Responses in both mCSCC cohorts were durable.
Clinical trial identification
NCT02760498.
Editorial acknowledgement
Tiffany DeSimone, PhD of Prime, New York, NY, funded by Regeneron Pharmaceuticals, Inc. and Sanofi.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc. and Sanofi.
Funding
Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure
D. Rischin: Research grant / Funding (institution), Non-remunerated activity/ies: Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: MSD; Research grant / Funding (institution), Non-remunerated activity/ies: GSK; Research grant / Funding (institution), Non-remunerated activity/ies: BMS; Research grant / Funding (institution): Roche. A.M. Lim: Travel / Accommodation / Expenses: BMS. C.D. Schmults: Advisory / Consultancy, Research grant / Funding (self): Regeneron Pharmaceuticals, Inc.; Research grant / Funding (self): Genentech Novartis; Advisory / Consultancy, Steering committee: Castle Biologics. N.I. Khushalani: Shareholder / Stockholder / Stock options: Bellicum Pharmaceuticals; Shareholder / Stockholder / Stock options: Mazor Robotics; Shareholder / Stockholder / Stock options: TransEnterix, Inc; Shareholder / Stockholder / Stock options: Amarin Corporation; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: EMD Serono; Advisory / Consultancy, Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc. ; Advisory / Consultancy, Research grant / Funding (institution): HUYA Bioscience International; Advisory / Consultancy: Genentech; Advisory / Consultancy: Array BioPharma; Advisory / Consultancy: Immunocore; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Amgen. B.G. Hughes: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Eisai; Advisory / Consultancy: Merck; Research grant / Funding (institution): Amgen. D. Schadendorf: Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc.; Advisory / Consultancy: Amgen ; Advisory / Consultancy: Leo Pharma; Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Merck-EMD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Incyte ; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Advisory / Consultancy, Research grant / Funding (institution): MSD; Honoraria (self), Steering committee : 4SC; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Array; Advisory / Consultancy, Research grant / Funding (institution): Philiogen. L.A. Dunn: Advisory / Consultancy, Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc.; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Pfizer. A.L.S. Chang: Advisory / Consultancy, Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc.; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Galderma; Research grant / Funding (institution): Nuskin. A. Hauschild: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD/Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Provectus; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Merck Serono; Advisory / Consultancy, Research grant / Funding (institution): Philogen; Advisory / Consultancy, Research grant / Funding (institution): Regeneron Pharmaceuticals, Inc.; Advisory / Consultancy: OncoSec. C. Ulrich: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Galderma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Almirall. T. Eigentler: Advisory / Consultancy: Sanofi-Genzyme; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD. M.R. Migden: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Regeneron Pharmaceuticals, Inc.; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Sanofi-Genzyme; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sun Pharmaceuticals. A.C. Pavlick: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Regeneron Pharmaceuticals, Inc.; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Array; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Seattle Genetics; Honoraria (self), Advisory / Consultancy: Amgen; Research grant / Funding (institution): Celldex; Research grant / Funding (institution): Porance. E. Stankevich: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc.; Shareholder / Stockholder / Stock options: Celgene; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb; Shareholder / Stockholder / Stock options: Merck. S. Li: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. I. Lowy: Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. M.G. Fury: Shareholder / Stockholder / Stock options, Full / Part-time employment: Regeneron Pharmaceuticals, Inc. A. Guminski: Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Regeneron Pharmaceuticals, Inc. ; Advisory / Consultancy, Travel / Accommodation / Expenses: Sun Pharma; Advisory / Consultancy: Eisai; Advisory / Consultancy: MSD Oncology; Advisory / Consultancy: Prime Oncology; Travel / Accommodation / Expenses: Medivation/Astellas; Travel / Accommodation / Expenses: Merck KGaA. All other authors have declared no conflicts of interest.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract